Skip to main content

Advertisement

SpringerLink
Log in

Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose.

To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma.

Methods.

IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly.

Results.

There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects.

Conclusions.

This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sciarrino E, Simonetti RG, Le Mol S, Pagliario L (1985) Adriamycin for hepatocellular carcinoma. Cancer 56:2751–2755

    CAS  PubMed  Google Scholar 

  2. Olweny CLM, Toy T, Katogole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H (1975) Treatment of hepatocellular carcinoma with adriamycin. Cancer 36:1250–1257

    CAS  PubMed  Google Scholar 

  3. Vogel CL, Bayley AL, Brooker RJ, Anthony PP, Ziegler JL (1977) A phase II study of adriamycin (NSC 123126) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39:1923–1929

    CAS  PubMed  Google Scholar 

  4. Shouval D, Rager-Zisman B, Quar P, Shafritz DA, Bloom BR, Reed LM (1983) Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus. J Clin Invest 72:707–717

    CAS  PubMed  Google Scholar 

  5. Lai CL, WM PC, Lok ASF, Lin HJ, Hgan H, Lau JY, Chung HT, Ng MM, Yooh EK, Arnold M (1984) Recombinant leukocyte A interferon vs adriamycin in hepatocellular carcinoma: a randomized trial. Hepatology 4:1015 [Abstr]

    Google Scholar 

  6. Welander CG, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ (1985) Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 35:721–729

    CAS  PubMed  Google Scholar 

  7. Von Hoff DO (1991) In vitro data supporting interferon plus cytotoxic agent combinations. Semin Oncol 18 [Suppl 7]:58

  8. Welarden CE (1987) Overview of preclinical and clinical studies of interferon-2b in combination with cytotoxic drugs. Invest New Drugs 5 [Suppl 47]

  9. Walter W, Stein U (1994) Influence of cytokines on mdr-1 expression in human colon carcinoma cell lines: Increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 120:471

    PubMed  Google Scholar 

  10. Welarden C (1987) Use of interferon in the treatment of ovarian cancer as single agent and in combination with cytotoxic drugs. Cancer 59:617

    PubMed  Google Scholar 

  11. Welander CE, Muss HB, Homesley HD, Spiegel RJ (1985) Phase II trial of combined human interferon alpha 2 (rIFN2) and doxorubicin (DOX) in advanced solid tumors. Proc Am Soc Clin Oncol 4:220

    Google Scholar 

  12. Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P, Livingstone AS, Ardalan B, Levi Ju, Parker T, Schiff ER (1994) A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol 17:393–395

    CAS  PubMed  Google Scholar 

  13. Link JS, Bateman Jr, Parolgy WS, Durkin WJ, Peters RL (1977) 5-Fluorouracil in hepatocellular carcinoma. Cancer 39:1936–1939

    CAS  PubMed  Google Scholar 

  14. Jian W, Wu Z, He Y, Diasio RB (1997) Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-Fluorouracil-based chemotherapy. Clin Cancer Res 3:395

    Google Scholar 

  15. Benson AB, Mitchell E, Abramson N, Klenke B, Ritch P, Burnham J, McGuirt C, Levin J, Hohneker J (1999) A multicenter, phase II trial of oral eniluracil plus 5-FU in patients with inoperable hepatocellular carcinoma. Proc Am Soc Clin Oncol 18:256a

    Google Scholar 

  16. Ardalan B, Restrepo A, Deng Z, Sridhar KS, Feun L, Richman S, Sparling L, Watson C, Triplett N (1996) Phase I–II trial of high dose 24-h infusion of fluorodeoxyuridine (5FUDR) in patients with colorectal cancer. Proc Am Soc Clin Oncol 15:202

    Google Scholar 

  17. Ardalan B, Sparling L, Sridhar K, Hurley J, Feun L, Richman S, Hamilton K, Triplett N, Fayad D (1999) Phase II trial of high dose 24-h infusion of 5-fluoro-deoxyuridine (FUDR) in patients with metastatic colorectal cancers (previously failed multiple chemotherapeutic modalities). Proc ASCO:8:249a

  18. Fong Y, Kemeny N, Lawrence TS (2001) Cancer of the liver and biliary tree in cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Principles and practice of oncology. Lippincott, Philadelphia

  19. Sulini Y, Virkajarvi N, Raumo H, Paakko P (1996) Expression of p-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Path 49:470

    PubMed  Google Scholar 

  20. Leung TWT, Wy Lau, Tang A, Zee B, Johnson PJ (2000) Patient characteristics that predict after systemic PIAF chemotherapy for hepatocellular carcinoma. Proc Am Soc Clin Oncol 19:278

    Google Scholar 

  21. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chung V, Carrasco H, Rohm Chase J, Fischer H, Jones D, Levin B (1994) Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicities and patient survival. J Clin Oncol 12:1204–1211

    Google Scholar 

  22. Ihde D, Matthews MJ, Makuch RW, McIntire KR, Eddy JL, Sceff LB (1985) Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Am J Med 78:399–406

    Google Scholar 

  23. Koda J, Venook A, Walser E, Goodwin S, Morse M, Van Thiel D, Qaseem T, Berslan (2001) A multicenter, phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma. Proc Am Soc Clin Oncol 20:168a

    Google Scholar 

  24. Boucher EJ, Marchetti C, Roland Y, Duvauferier R, Guyaden D, Raoul J (2001) Curative intra-arterial 131 iodine labeled lipiodol: an alternative for patients with hepatocellular carcinoma. Proc Am Soc Clin Oncol 20:167a

    Google Scholar 

  25. Leung TWT, Feun L, Posey J, Stagg RJ, Levy MD, Venook AP (2002) A phase II study of T138067- sodium in patients (pts) with unresectable hepatocellular carcinoma. Proc Am Soc Clin Onc 21:144a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 N.W. 12th Avenue, Miami, Fla., USA

    Lynn G. Feun, Christopher O'Brien, Enrique Molina, Miguel Rodriguez, Lenox Jeffers, Eugene R. Schiff, Angela Marini, Niramol Savaraj & Bach Ardalan

Authors
  1. Lynn G. Feun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Enrique Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miguel Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lenox Jeffers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eugene R. Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Angela Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Niramol Savaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bach Ardalan
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by a grant from Roche Laboratories

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feun, L.G., O'Brien, C., Molina, E. et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. J Cancer Res Clin Oncol 129, 17–20 (2003). https://doi.org/10.1007/s00432-002-0398-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-002-0398-2

Keywords.

Search

Navigation